#ESMO26 DASL-HiCaP 主席讨论嘉宾 -- @Silke_Gillessen
BL 风险和患者选择方面的差异，可能解释 STAMPEDE M0、ENZARAD、DASL-HiCaP 治疗效果的差异
仅限 N1 患者，ARPI 对 MFS 的获益：
◾️STAMPEDE M0: HR 0.49, 95%CI 0.38-0.64
◾️ENZARAD: HR 0.43, 95%CI 0.20-0.92
◾️DASL-HiCaP: HR 0.39, 95%CI 0.19-0.81
23 浏览 · 0 赞 · 1 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：Zach Klaassen · x.com